<code id='D47E6AEE03'></code><style id='D47E6AEE03'></style>
    • <acronym id='D47E6AEE03'></acronym>
      <center id='D47E6AEE03'><center id='D47E6AEE03'><tfoot id='D47E6AEE03'></tfoot></center><abbr id='D47E6AEE03'><dir id='D47E6AEE03'><tfoot id='D47E6AEE03'></tfoot><noframes id='D47E6AEE03'>

    • <optgroup id='D47E6AEE03'><strike id='D47E6AEE03'><sup id='D47E6AEE03'></sup></strike><code id='D47E6AEE03'></code></optgroup>
        1. <b id='D47E6AEE03'><label id='D47E6AEE03'><select id='D47E6AEE03'><dt id='D47E6AEE03'><span id='D47E6AEE03'></span></dt></select></label></b><u id='D47E6AEE03'></u>
          <i id='D47E6AEE03'><strike id='D47E6AEE03'><tt id='D47E6AEE03'><pre id='D47E6AEE03'></pre></tt></strike></i>

          hotspot

          hotspot

          author:explore    Page View:724
          Cambridge: AbbVie
          The pharma giant AbbVie spent nearly $4 million on lobbying in the first three months of 2022 — nearly a million dollars more than the company has ever spent in a single quarter. Ruby Wallau for STAT

          WASHINGTON — The pharma giant AbbVie spent nearly $4 million on lobbying in the first three months of 2022 alone — more than any other drugmaker spent in the same period, and nearly a million dollars more than the company spent in the same period last year.

          AbbVie was the seventh-highest corporate lobbying spender last quarter, ahead of giants like Lockheed Martin, CVS Health, and, AT&T, federal records show.

          advertisement

          The number is eye-popping even for the pharmaceutical industry, which is known for its omnipresence on Capitol Hill, and its nearly unlimited lobbying budgets.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          comprehensive

          Supreme Court strikes down use of affirmative action
          Supreme Court strikes down use of affirmative action

          ActivistsdemonstratedastheSupremeCourtheardoralargumentsonapairofaffirmativeactioncasesinOctober2022

          read more
          Readout Newsletter: New research from Sanofi, Regeneron, etc.
          Readout Newsletter: New research from Sanofi, Regeneron, etc.

          HyacinthEmpinado/STATWanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup togetourbiote

          read more
          Psychedelics group wrestles with new pharma identity
          Psychedelics group wrestles with new pharma identity

          OliviaGoldhill/STATDENVER—Hecouldhavebeenarockstar,areligiousicon,thewayecstaticapplausefromthousand

          read more

          The FDA weighs the risks of candy

          AdobeWASHINGTON—M&Ms,Reese’s,gummybears,andevencottoncandymadeanappearanceattheFoodandDrugAdmini